Precipio (NASDAQ:PRPO) vs. Cytek BioSciences (NASDAQ:CTKB) Head to Head Analysis

Precipio (NASDAQ:PRPO) and Cytek BioSciences (NASDAQ:CTKB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Valuation and Earnings

This table compares Precipio and Cytek BioSciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Precipio $6.09 million 11.15 -$10.63 million N/A N/A
Cytek BioSciences N/A N/A N/A N/A N/A

Cytek BioSciences has lower revenue, but higher earnings than Precipio.

Insider and Institutional Ownership

11.9% of Precipio shares are held by institutional investors. 6.7% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


This table compares Precipio and Cytek BioSciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Precipio -124.55% -55.13% -40.36%
Cytek BioSciences N/A N/A N/A

Analyst Recommendations

This is a summary of recent ratings for Precipio and Cytek BioSciences, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precipio 0 0 1 0 3.00
Cytek BioSciences 0 1 3 0 2.75

Precipio presently has a consensus target price of $7.00, suggesting a potential upside of 134.11%. Cytek BioSciences has a consensus target price of $27.33, suggesting a potential upside of 2.07%. Given Precipio’s stronger consensus rating and higher probable upside, analysts plainly believe Precipio is more favorable than Cytek BioSciences.


Precipio beats Cytek BioSciences on 5 of the 9 factors compared between the two stocks.

Precipio Company Profile

Precipio, a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Cytek BioSciences Company Profile

Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.

Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with's FREE daily email newsletter.